On October 5, Charles River Laboratories rose 5.34% in Regular Trading, trading near $306, with Turnover of $142 million. This move follows UBS's substantial target price increase to $357 from $175 and the company's new contract providing plasmid copy number testing for probiotic candidates targeting muscle health in GLP-1 weight loss therapies.

UBS analysts upgraded Charles River to Buy from Neutral, setting the highest price target among major banks and citing strong margin potential in Discovery and Safety Assessment services. Simultaneously, the new NorthStrive Biosciences agreement positions Charles River at the intersection of the $100B GLP-1 market and next-generation microbiome therapies, expanding its manufacturing quality control offerings. These developments build on recent analyst optimism from RBC and Argus, both projecting significant upside.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)